Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
main-content
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 5-6/2020

25.10.2019 | original article

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study

verfasst von: Peter Peichl, Rieke Alten, Mauro Galeazzi, Hanns-Martin Lorenz, Hubert Nüßlein, Federico Navarro, Yedid Elbez, Melanie Chartier, Roland Hackl, Christiane Rauch, Sean E Connolly

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

AbataCepT In rOutiNe clinical practice (ACTION; NCT02109666) was a 2-year international observational study of patients with moderate to severe rheumatoid arthritis.

Methods

Baseline characteristics, abatacept retention rates, and clinical outcomes were compared by treatment line in the Austrian cohort of ACTION.

Results

Of 100 patients enrolled in Austria, 98 (98.0%) were evaluable: 33/98 (33.7%) biologic naïve and 65/98 (66.3%) with ≥1 prior biologic failure. At baseline, biologic-naïve patients had shorter disease duration and lower concomitant corticosteroid use than biologic-failure patients. Overall crude abatacept retention rate was 60.5% and retention rate was higher in biologic-naïve (65.1%) versus biologic-failure (58.0%) patients. Good/moderate EULAR (European League Against Rheumatism) response rates were 85.7% in biologic-naïve and 100% in biologic-failure patients.

Conclusions

In the Austrian cohort of ACTION, overall abatacept retention at 2 years was high, with higher retention rates in patients receiving abatacept as an earlier treatment line. Good/moderate EULAR response rate was higher in biologic-failure than in biologic-naïve patients.
Vorheriger Artikel Romosozumab: a novel bone anabolic treatment option for osteoporosis?
Nächster Artikel Aortic valve stenosis awareness in Austria—results of a nationwide survey in 1001 subjects
Literatur
1.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. CrossRef
2.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–22. CrossRef
3.
European Commission. The 2018 ageing report: economic and budgetary projections for the EU member states (2016–2070). 2018.
4.
Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. CrossRef
5.
Smolen JS. Treat-to-target as an approach in inflammatory arthritis. Curr Opin Rheumatol. 2016;28(3):297–302. CrossRef
6.
Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheumatol. 2009;61(5):560–8. CrossRef
7.
8.
9.
Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3(2):e538. CrossRef
10.
Nüßlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2‑year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014;15(1):14. CrossRef
11.
Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99. PubMed
12.
Prodinger B, Ndosi M, Nordenskiold U, Stamm T, Persson G, Andreasson I, et al. Rehabilitation provided to patients with rheumatoid arthritis: a comparison of three different rheumatology clinics in Austria, Sweden and the UK from the perspectives of patients and health professionals. J Rehabil Med. 2015;47(2):174–82. CrossRef
13.
Puchner R, Hochreiter R, Pieringer H, Vavrovsky A. Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs. BMC Musculoskelet Disord. 2017;18(1):7. CrossRef
14.
Alten R, Mariette X, Nuesslein H, Galeazzi M, Navarro F, Chartier M, et al. Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2‑year results from the real-world ACTION study. Ann Rheum Dis. 2017;76(Suppl 2):FRI245.
15.
Alten R, Lorenz HM, Mariette X, Nüßlein H, Galeazzi M, Navarro F, et al. Abatacept retention rates, overall and by participating country, and prognostic factors of retention in patients with RA: 2‑year results from a real-world observational study. In: ACR/ARHP Annual Scientific Meeting, San Diego, CA, USA, November 4–8. 2017. p. Poster 1468.
16.
17.
18.
World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277(11):925–6. CrossRef
19.
ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med. 2001;47(3):199–203.
20.
21.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988;31(3):315–24. CrossRef
22.
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745–57. CrossRef
23.
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–13. CrossRef
24.
Stamm TA, Reichardt B, Zwerina J, Ritschl V, Nell-Duxneuner V. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011: a retrospective analysis of 72 % of the population. Wien Klin Wochenschr. 2018;130(7–8):230–7. CrossRef
25.
26.
27.
28.
Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, et al. Economic considerations and patients’ preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Ann Rheum Dis. 2017;76(1):126–32. CrossRef
29.
Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, et al. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int. 2014;34(1):1–9. CrossRef
30.
Emery P, Solem C, Majer I, Cappelleri JC, Tarallo M. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatol Int. 2015;35(11):1837–49. CrossRef
31.
Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. CrossRef
32.
Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014;73(11):2010–21. CrossRef
33.
Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, et al. The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open. 2015;1:e40. CrossRef
34.
35.
Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, et al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456–60. CrossRef
Metadaten
Titel
Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study
verfasst von
Peter Peichl
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Hubert Nüßlein
Federico Navarro
Yedid Elbez
Melanie Chartier
Roland Hackl
Christiane Rauch
Sean E Connolly
Publikationsdatum
25.10.2019
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2020
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-019-00710-8

Weitere Artikel der Ausgabe 5-6/2020

Wiener Medizinische Wochenschrift 5-6/2020 Zur Ausgabe

main topic

Treatment of hypophosphatasia

editorial

Osteoporosis and other musculoskeletal disorders—treatment is challenging!

original article

Aortic valve stenosis awareness in Austria—results of a nationwide survey in 1001 subjects

main topic

Multidisciplinary patient care in X‐linked hypophosphatemic rickets: one challenge, many perspectives

review

New developments in the management of achondroplasia

main topic

Romosozumab: a novel bone anabolic treatment option for osteoporosis?